文献速递胸部

大分割放射治疗在局部晚期非小细胞肺癌管理中的应用:意大利放射肿瘤学会(AIRO)肺部工作组的一项叙述性文献综述

Hypofractionated radiation therapy in the management of locally advanced NSCLC: a narrative review of the literature on behalf of the Italian Association of Radiation Oncology (AIRO)-Lung Working Group.
PubMed 文献 · Radiol Med · 2018-10-27

该叙述性综述系统检索2007年以来局部晚期非小细胞肺癌根治性大分割放疗(合并或不合并化疗)的研究,共纳入29项研究、2614例患者。分同步放化疗组与单纯放疗组汇总剂量、生存及食管和肺毒性范围,认为大分割放疗似乎安全,但需进一步研究。

要点

  • 单纯放疗组剂量45–85.5 Gy,分次剂量2.4–4 Gy;同步放化疗组剂量52.5–75 Gy,分次剂量2.4–3.5 Gy。
  • 同步放化疗组1年总生存28–95%,单纯放疗组51.3–95%。
  • 急性≥3级食管炎单纯放疗组0–15%,同步放化疗组急性2–3级食管炎3–41.7%。

核心结论

  • 大分割放疗在局部晚期非小细胞肺癌患者中似乎安全。
  • 多项研究令人鼓舞的生存结果提示,大分割放疗方案应在未来进一步研究。

研究设计与样本

  • 意大利放射肿瘤学会(AIRO)肺部工作组开展的叙述性文献综述,系统检索2007年以来发表的文献。
  • 纳入局部晚期非小细胞肺癌接受根治性大分割放疗(合并或不合并同步化疗)、最小分次剂量2.4 Gy的研究。
  • 共纳入29项研究、2614例患者,分为同步放化疗组与单纯放疗组。

诊断标准与关键数值

  • 单纯放疗组:剂量45–85.5 Gy,分次剂量2.4–4 Gy;2年无进展生存13–57.8%,1年、2年、3年总生存分别为51.3–95%、22–68.7%、7–32%。
  • 单纯放疗组:急性≥3级食管炎0–15%,晚期食管毒性0–16%;急性肺炎0–44%,晚期肺炎0–47%,多为≤G3。
  • 同步放化疗组:剂量52.5–75 Gy,分次剂量2.4–3.5 Gy;2年无进展生存19–57.8%,1年、2年、3年总生存分别为28–95%、38.6–68.7%、31–44%。
  • 同步放化疗组:急性2级和3级食管炎3–41.7%,晚期食管毒性0–8.3%;急性肺炎0–23%,晚期肺炎0–47%。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文结论指出大分割放疗方案应在未来进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

A systematic literature was performed to assess the benefit in terms of effectiveness and feasibility of hypofractionated radiotherapy (HypoRT), with or without chemotherapy (CT), in the treatment of locally advanced non-small cell lung cancer (NSCLC). We have identified all studies, published from 2007 onwards, on patients with locally advanced NSCLC treated with HypoRT with radical intent, with a minimal dose per fraction of 2.4 Gy, with or without concurrent chemotherapy. Twenty-nine studies were identified, for a total of 2614 patients. Patients were divided in the concurrent chemo-radiation therapy group (CT-RT) and radiotherapy alone (RT). In RT group, the delivered dose ranged from 45 to 85.5 Gy, with a dose/fraction from 2.4 to 4 Gy. Actuarial 2-year PFS ranged from 13 to 57.8%, and 1, 2- and 3-year overall survival (OS) ranged from 51.3 to 95%, from 22 to 68.7%, and from 7 to 32%, respectively. Acute Grade ≥ 3 esophagitis occurred in 0-15%, while late esophageal toxicity was 0-16%. Acute pneumonitis occured in 0-44%, whereas late pneumonitis occured in 0-47%, most commonly grade ≤ G3. In CT-RT group, the delivered dose ranged from 52.5 to 75 Gy, with a dose/fraction ranging from 2.4 to 3.5 Gy. Actuarial 2-year PFS ranged from 19 to 57.8%, and OS at 1, 2 and 3 years ranged from 28 to 95%, 38.6 to 68.7%, and 31 to 44%, respectively. Acute Grade 2 and 3 esophagitis occurred in 3-41.7%, while late esophageal toxicity occurred in 0-8.3%. Acute pneumonitis ranged from 0 to 23%, whereas late pneumonitis occured 0-47%. HypoRT seems to be safe in patients with locally advanced NSCLC. The encouraging survival results of several studies analyzed suggest that hypofractionated radiation schemes should be further investigated in the future.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Parisi G, Mazzola R, Ciammella P, et al. Hypofractionated radiation therapy in the management of locally advanced NSCLC: a narrative review of the literature on behalf of the Italian Association of Radiation Oncology (AIRO)-Lung Working Group. Radiol Med. 2018. PMID: 30368721. doi:10.1007/s11547-018-0950-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。